Since Elevidys' accelerated approval in 2023, experts have been clamoring for more data, particularly in older and ...

Shares of Sarepta Therapeutics cratered on Wednesday after the biopharmaceutical company trimmed its full-year forecast for ...

Sarepta has submitted a request to the FDA to include the death case in Elevidys’ label, and the agency plans to review the ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

Sarepta Therapeutics is meeting with the FDA in June to discuss expanding the use of its Duchenne muscular dystrophy gene ...

Sarepta Therapeutics shares are sinking after the company releases its first-quarter results after Tuesday's closing bell.

Already facing headwinds caused by a patient’s death and treatment delays, the biotech now may have to contend with a less ...

The approval was based on the therapy’s safety and efficacy data, including muscle health and longer-term functional outcomes ...

Uncertainty around ELEVIDYS sales impact Sarepta Therapeutics, Inc. Click here to find out why I downgraded SRPT stock to a ...

Sarepta Therapeutics Q1 2025 revenue beat expectations, but EPS missed, and cash reserves dropped significantly. Click here ...

Shares of Sarepta Therapeutics fell after the company cut its full-year outlook, citing significant pressures hurting the broader biotech market. The stock tumbled 21%, to $36.75, in after-hours ...

Sarepta Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estimate of losses of ...